Does excluding subjects with features similar to IPF affect the results of the INBUILD trial of nintedanib?

Autor:	Yoshikazu Inoue, Susanne Stowasser, Bruno Crestani, Athol U. Wells, Vincent Cottin, Luca Richeldi, Rainer-Georg Goeldner, Maria Molina Molina, Rozsa Schlenker-Herceg
Rok vydání:	2020
Předmět:	Oncology chemistry.chemical_compound medicine.medical_specialty chemistry business.industry Internal medicine Medicine Nintedanib business Affect (psychology)
Zdroj:	ILD / DPLD of known origin.
DOI:	10.1183/13993003.congress-2020.740
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b382495492617155dce95ced60db2514 https://doi.org/10.1183/13993003.congress-2020.740 Zobrazit plný text záznamu